Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Aerpio Therapeutics Inc. (Cincinnati, Ohio) said a combination of its AKB-9778 and Lucentis ranibizumab was superior to Lucentis alone
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury